343 related articles for article (PubMed ID: 22735051)
1. Phosphodiesterase 4 and its inhibitors in inflammatory diseases.
Jin SL; Ding SL; Lin SC
Chang Gung Med J; 2012; 35(3):197-210. PubMed ID: 22735051
[TBL] [Abstract][Full Text] [Related]
2. Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors.
Saldou N; Obernolte R; Huber A; Baecker PA; Wilhelm R; Alvarez R; Li B; Xia L; Callan O; Su C; Jarnagin K; Shelton ER
Cell Signal; 1998 Jun; 10(6):427-40. PubMed ID: 9720765
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
4. Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors.
Wang H; Peng MS; Chen Y; Geng J; Robinson H; Houslay MD; Cai J; Ke H
Biochem J; 2007 Dec; 408(2):193-201. PubMed ID: 17727341
[TBL] [Abstract][Full Text] [Related]
5. PDE4B as a microglia target to reduce neuroinflammation.
Pearse DD; Hughes ZA
Glia; 2016 Oct; 64(10):1698-709. PubMed ID: 27038323
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of a novel, orally active PDE4 inhibitor.
Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V
Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962
[TBL] [Abstract][Full Text] [Related]
7. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages.
Jin SL; Lan L; Zoudilova M; Conti M
J Immunol; 2005 Aug; 175(3):1523-31. PubMed ID: 16034090
[TBL] [Abstract][Full Text] [Related]
8. Elevated PDE4C level serves as a candidate diagnostic biomarker and correlates with poor survival in thyroid carcinoma.
Wang Y; Zhang Y; Li Y; Huang J
Sci Rep; 2024 Mar; 14(1):6813. PubMed ID: 38514754
[TBL] [Abstract][Full Text] [Related]
9. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
Konrad FM; Bury A; Schick MA; Ngamsri KC; Reutershan J
PLoS One; 2015; 10(4):e0121725. PubMed ID: 25909327
[TBL] [Abstract][Full Text] [Related]
10. Synergic PDE3 and PDE4 control intracellular cAMP and cardiac excitation-contraction coupling in a porcine model.
Mika D; Bobin P; Lindner M; Boet A; Hodzic A; Lefebvre F; Lechène P; Sadoune M; Samuel JL; Algalarrondo V; Rucker-Martin C; Lambert V; Fischmeister R; Vandecasteele G; Leroy J
J Mol Cell Cardiol; 2019 Aug; 133():57-66. PubMed ID: 31158360
[TBL] [Abstract][Full Text] [Related]
11. PDE4 associates with different scaffolding proteins: modulating interactions as treatment for certain diseases.
McCahill AC; Huston E; Li X; Houslay MD
Handb Exp Pharmacol; 2008; (186):125-66. PubMed ID: 18491051
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
Page CP; Spina D
Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
[TBL] [Abstract][Full Text] [Related]
13. Update on the therapeutic potential of PDE4 inhibitors.
Dyke HJ; Montana JG
Expert Opin Investig Drugs; 2002 Jan; 11(1):1-13. PubMed ID: 11772317
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
Bhat A; Ray B; Mahalakshmi AM; Tuladhar S; Nandakumar DN; Srinivasan M; Essa MM; Chidambaram SB; Guillemin GJ; Sakharkar MK
Pharmacol Res; 2020 Oct; 160():105078. PubMed ID: 32673703
[TBL] [Abstract][Full Text] [Related]
15. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.
Manning CD; Burman M; Christensen SB; Cieslinski LB; Essayan DM; Grous M; Torphy TJ; Barnette MS
Br J Pharmacol; 1999 Dec; 128(7):1393-8. PubMed ID: 10602317
[TBL] [Abstract][Full Text] [Related]
16. PDE4D phosphorylation: A coincidence detector integrating multiple signaling pathways.
Mika D; Conti M
Cell Signal; 2016 Jul; 28(7):719-24. PubMed ID: 26562185
[TBL] [Abstract][Full Text] [Related]
17. NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues.
Yougbare I; Morin C; Senouvo FY; Sirois C; Albadine R; Lugnier C; Rousseau E
Am J Physiol Lung Cell Mol Physiol; 2011 Oct; 301(4):L441-50. PubMed ID: 21784969
[TBL] [Abstract][Full Text] [Related]
18. Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).
Cameron RT; Coleman RG; Day JP; Yalla KC; Houslay MD; Adams DR; Shoichet BK; Baillie GS
Biochem Pharmacol; 2013 May; 85(9):1297-305. PubMed ID: 23473803
[TBL] [Abstract][Full Text] [Related]
19. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs.
Zhang HT
Curr Pharm Des; 2009; 15(14):1688-98. PubMed ID: 19442182
[TBL] [Abstract][Full Text] [Related]
20. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant.
Erdogan S; Houslay MD
Biochem J; 1997 Jan; 321 ( Pt 1)(Pt 1):165-75. PubMed ID: 9003416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
